Danaher Corporation

Danaher Corporation

DHR

$230.40

Updated: 03/11/2026, 21:03:20

Market Cap
$161.96B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

USD
NYSE
CEO: Julie Sawyer Montgomery
Employees: 59,000
https://www.danaher.com
Asset Summaries
Latest generated summaries for DHR

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
DHR-10-k-fy2025.html2.8 MBtext/htmlENFiled 24/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 67 KPI observations

Revenue

$24.6B

FY 2025 · Reported

Net income

$3.6B

FY 2025 · Reported

Gross margin

59.1%

FY 2025 · Calculated

Free cash flow

$5.3B

FY 2025 · Calculated

R&D intensity

6.5%

FY 2025 · Calculated

Share repurchases

$3.1B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Biotechnology segment offerings
Life Sciences segment offerings

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Danaher: 15+ operating companies across Biotechnology, Life Sciences and Diagnostics segments; facilities in ~50 countries; DBS culture; direct sales model with high recurring revenue.

98%
Source evidence
“Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics).”

Reportable segments

Three segments: Biotechnology, Life Sciences, Diagnostics.

99%
Source evidence
“organized under three segments (Biotechnology, Life Sciences and Diagnostics)”

Segments referenced in 2025 results

Biotechnology, Diagnostics, Life Sciences

95%
Source evidence
“higher core sales in the Biotechnology segment and, to a lesser extent, the Diagnostics segment, partially offset by lower core sales in the Life Sciences segment”

Biotechnology segment customer base

Biotechnology customers: pharma/biopharma companies, CMOs, biotech companies, translational medicine institutions, academic/research and clinical professionals.

94%
Source evidence
“Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations.”

Distribution model

Biotechnology businesses sell through direct sales personnel and independent distributors; company overall primarily uses a direct sales model.

93%
Source evidence
“The business sells to customers through direct sales personnel and independent distributors.”

Non-U.S. sales channel structure

Most non-U.S. sales via local subsidiaries; reps/distributors used in low-volume countries

90%
Source evidence
“In countries with low sales volumes, the Company generally sells through representatives and distributors.”

Biotechnology segment offerings

Biotechnology: bioprocessing (media, buffers, chromatography resins, filtration, aseptic fill finish, single-use technologies) plus discovery & medical (lab filtration, diagnostic assay reagents, healthcare filtration); key brands CYTIVA and PALL.

97%
Source evidence
“market their products and services under several key brands including CYTIVA and PALL. Manufacturing facilities are located in North America, Europe and Asia.”

Life Sciences segment offerings

Life Sciences: instruments (flow cytometry/lab automation, mass spectrometry, microscopy), consumables (custom DNA/RNA oligonucleotides, gene fragments, antibodies/reagents/assays), and filtration/separation/purification products.

96%
Source evidence
“The Life Sciences segment consists of the life sciences instruments business, the life sciences consumables business and the filtration, separation and purification business.”

2025 sales by geographic destination

2025 sales by destination: North America includes 41% in the United States; high-growth markets defined as Eastern Europe, Middle East, Africa, Latin America (incl. Mexico) and Asia excl. Japan, Australia, New Zealand.

90%
Source evidence
“Sales in North America includes 41% in the United States. The Company defines North America as the United States and Canada.”

Operations and dependencies

Biotechnology manufacturing footprint

Biotechnology manufacturing facilities located in North America, Europe and Asia.

93%
Source evidence
“Manufacturing facilities are located in North America, Europe and Asia.”

Positioning and strategy

Pending acquisition of Masimo Corporation

Pending acquisition of Masimo Corporation (described in Note 2).

95%
Source evidence
“including our pending acquisition of Masimo Corporation, which is further described in Note 2”

Historical portfolio acquisitions

Key acquisitions: Leica Microsystems (2005), AB Sciex & Molecular Devices (2010), Beckman Coulter (2011), Pall (2015), Phenomenex (2016), IDT (2018), Aldevron (2021), Abcam (2023), Cytiva (2020).

95%
Source evidence
“including the acquisitions of AB Sciex and Molecular Devices in 2010, Beckman Coulter in 2011, Pall in 2015, Phenomenex in 2016, IDT in 2018, Aldevron in 2021 and Abcam in 2023.”

Monoclonal antibody demand drives bioprocessing consumables

Continued consumables growth driven by monoclonal antibody demand and offerings across the biologics workflow

90%
Source evidence
“including continued growth in consumables driven by monoclonal antibody demand and the Company's product offerings across the biologics workflow”

Three strategic priorities

Strategic priorities: DBS tools/culture as competitive moat, strategic capital allocation into science & technology markets, and attracting/retaining exceptional talent.

97%
Source evidence
“Danaher strives to create shareholder value primarily through three strategic priorities:”

Growth priorities and investment in technological change

Priorities include high-growth market expansion, M&A and partnerships, higher-margin innovation, salesforce effectiveness, DBS-driven cost efficiency, and investment against rapid technological change (AI, automation, digitization)

90%
Source evidence
“rapid technological development (particularly with respect to computing, automation, AI, mobile connectivity and digitization) in most of the Company's served markets”

Risks, financing, and outlook

Operational cost inflation exposure

Operational costs (energy, materials, labor, distribution) subject to inflationary market pressures

90%
Source evidence
“Our operational costs, including the cost of energy, materials, labor, distribution and our other operational and facilities costs are subject to market conditions, including inflationary pressures.”

2026 segment outlook assumptions

2026: Biotech Bioprocessing growth similar to 2025 (mAb-driven consumables); Life Sciences modest end-market improvement; Diagnostics higher growth as China policy headwinds ease

90%
Source evidence
“In 2026 within the Biotechnology segment, the Company is assuming that the Bioprocessing sales growth trend will be similar to 2025, including continued growth in consumables driven by monoclonal antibody demand”

2025 incremental tariff costs and mitigation

2025 incremental tariff costs <$300M, largely offset via footprint changes, supply chain adjustments, surcharges and productivity actions

95%
Source evidence
“the Company incurred incremental tariff costs for 2025 of less than $300 million.”

U.S. healthcare fraud and abuse laws

Subject to Anti-Kickback Statute, HIPAA fraud rules, False Claims Act qui tam actions, Civil Monetary Penalties Law, Open Payments Act

95%
Source evidence
“The U.S. Federal Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration”

U.S. export/import control and sanctions compliance

Compliance required with ITAR, EAR, OFAC sanctions, U.S. import regulation, and anti-boycott laws

90%
Source evidence
“the Export Administration Regulations administered by the U.S. Department of Commerce, Bureau of Industry and Security”

Healthcare reform and pricing scrutiny

PPACA, heightened U.S. pricing scrutiny, state pricing constraints, and similar China measures affect healthcare demand

90%
Source evidence
“Other countries, including China, have also introduced similar measures with the stated goals of containing healthcare costs, improving quality and/or expanding access.”

Data privacy and security laws (GDPR, HIPAA, state laws, data localization)

GDPR, HIPAA, U.S. state privacy laws, and China/Russia data-localization rules restrict data handling and transfers

90%
Source evidence
“Several other countries such as China and Russia have passed, and other countries are considering passing, privacy laws that require personal data relating to their citizens to be maintained on local servers or impose significant restrictions on data transfer.”

U.S. healthcare reimbursement and drug pricing regulation

PAMA CLFS pricing and IRA drug price negotiation may reduce customer reimbursement and pressure Danaher prices

90%
Source evidence
“the Inflation Reduction Act of 2022 contains various drug price negotiation, inflationary rebate and government-established pricing provisions with varying implementation dates and subjects manufacturers who fail to adhere to the government's interpretation of the law to penalties.”

Macroeconomic and policy sensitivity

Business sensitive to inflation, interest rates and U.S. administration change; may reduce demand, raise costs, and impair goodwill

95%
Source evidence
“Our business is sensitive to general economic conditions, such as elevated inflation and interest rates that have been experienced in domestic and international markets in recent years as well as the policy disruptions and uncertainties that have followed the 2025 change in administration in the U.S.”

China volume-based procurement program

China VBP price-lowering program has unfavorably impacted Danaher revenues and may continue to do so

95%
Source evidence
“China has introduced programs designed to lower prices for medical products and reduce healthcare costs (including a volume-based procurement program) that have unfavorably impacted our revenues and may continue to adversely affect our business and financial statements.”

Intense competition and pricing pressure

Intense competition, industry consolidation, private label/generic low-price products and disruptive technologies could reduce demand and pricing

95%
Source evidence
“The Company's competitors and customers have from time to time introduced, and may in the future introduce, private label, generic or low-cost products that compete with the Company's products at lower price points.”

AI-related uncertainty

AI development/deployment/use uncertainties may harm business and reputation.

93%
Source evidence
“Uncertainties with respect to the development, deployment, and use of artificial intelligence (“AI”) in our business and products may result in harm to our business and reputation.”

Debt and covenant risk

Acquisition-driven debt increases expected to continue; debt may limit operations, pressure credit ratings, and covenants pose compliance risk.

92%
Source evidence
“failure to comply with our indebtedness-related covenants could adversely affect our business and financial statements”

Tariff and policy uncertainty

Tariffs and trade-related impacts are a material risk; 2025 US administration change and Supreme Court decisions create policy and regulatory uncertainty including healthcare-related topics.

92%
Source evidence
“the 2025 change in the U.S. administration as well as recent Supreme Court decisions have resulted in policy, regulatory and economic changes, challenges and uncertainty, including with respect to tariffs and healthcare-related topics”

Trade policy and tariff uncertainty including IEEPA ruling

Feb 2026 Supreme Court ruled IEEPA does not authorize tariffs; administration plans new tariffs under alternative statutory authority; remaining impact uncertain

90%
Source evidence
“In February 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act ("IEEPA"), which the U.S. administration relied on to impose certain tariffs, does not authorize the administration to impose tariffs.”

Product innovation and commercialization risk

Growth depends on timely development/commercialization of new products; R&D may fail to generate significant revenue

90%
Source evidence
“If we do not develop innovative new and enhanced products and services on a timely basis, our offerings will become obsolete over time and our business and financial statements will suffer.”

Cybersecurity and data privacy exposure

Cyber-attack and data privacy risks; GDPR fines up to €20M or 4% of worldwide turnover; AI increases IT risk

90%
Source evidence
“failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states and other states subject to the GDPR may result in fines of up to €20 million or up to 4% of total worldwide annual turnover for the preceding financial year, whichever is higher”

Catastrophic loss to facilities and supply chains

Facilities/supply chains exposed to fire, flood, cyber-attack, pandemics, war; Hurricane Maria (2017, Puerto Rico) cited as precedent

90%
Source evidence
“such as the COVID-19 pandemic and the damage caused to our facilities by Hurricane Maria in Puerto Rico in 2017.”

Product defects and liability risk

Manufacturing/design defects or off-label use can lead to recalls, product liability claims and demand loss

85%
Source evidence
“Recalls, removals and product liability and similar claims (regardless of their validity or ultimate outcome) can result in significant costs, as well as negative publicity and damage to our reputation”

Climate change physical and regulatory risk

Climate physical risks can disrupt facilities/supply chains; new climate disclosure and sustainability regulations may raise costs

85%
Source evidence
“California laws requiring certain companies to disclose greenhouse gas emissions data and climate-related financial risks.”

Healthcare provider consolidation and purchasing leverage

Customers centralizing purchasing and forming GPOs to gain pricing leverage; risk of exclusion from market segments

85%
Source evidence
“Governmental and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services, centralizing purchasing, limiting the number of vendors that may participate in purchasing programs, forming group purchasing organizations”

AI-related technology risk

Growing incorporation of AI in the business exacerbates IT-system and security risks

80%
Source evidence
“These risks are exacerbated by the increasing importance of AI and the increasing incorporation of AI in our business.”

Material exposure graph

Danaher Corporation
Revenue Exposure

42% of 2025 sales destination is US (North America includes 41% in the United States), making US healthcare/demand conditions the single largest geographic revenue driver.

Relevance 90·Dependency 60·Confidence 90
Source evidence
“Sales in North America includes 41% in the United States.”
Pharmaceutical and biopharmaceutical companies
Customer Exposure

Pharma/biopharma customers across segments drive demand for bioprocessing and life sciences tools; healthcare cost-containment changes are a disclosed risk to demand.

Relevance 88·Dependency 70·Confidence 90
Source evidence
“Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations.”
United States
Regulatory Exposure

PAMA Medicare CLFS pricing and IRA drug price negotiation provisions may reduce reimbursement available to Danaher's lab customers and pressure prices.

Relevance 85·Dependency 65·Confidence 90
Source evidence
“PAMA introduced a multi-year pricing program for services payable under the Clinical Laboratory Fee Schedule ("CLFS") that is designed to bring Medicare allowable amounts in line with the amounts paid by private payors.”
Healthcare industry regulation
Regulatory Exposure

Businesses subject to extensive healthcare regulation; medical device introductions require clearances, recalls/cease-marketing possible, off-label marketing penalties possible.

Relevance 85·Dependency 60·Confidence 92
Source evidence
“Our businesses are subject to extensive regulation (including those applicable to the healthcare industry).”
tariffs
Demand Driver

Enacted/threatened tariffs raise input costs and may suppress demand; export restrictions could impair manufacturing, adversely affecting revenue and profitability.

Relevance 85·Dependency 60·Confidence 90
Source evidence
“If delayed or additional tariffs are implemented, the Company would incur additional tariff costs that could be material and the Company's revenue and profitability could be adversely impacted.”
China
Regulatory Exposure

China's volume-based procurement program has lowered medical product prices and unfavorably impacted Danaher revenues.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“China has introduced programs designed to lower prices for medical products and reduce healthcare costs (including a volume-based procurement program) that have unfavorably impacted our revenues”
Tariffs / trade policy
Cost Driver

Tariff and trade-related impacts are explicitly flagged as forward-looking risk items tied to 2025 US administration policy shifts.

Relevance 85·Dependency 50·Confidence 90
Source evidence
“projections of tariff or other trade-related impacts”
Bioprocessing consumables
Demand Driver

Monoclonal antibody demand drives consumables growth in the Biotechnology segment, the primary core sales growth contributor in 2025.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“the increase in core sales is primarily due to higher core sales in the Biotechnology segment”
Inflation
Demand Driver

Elevated inflation raises operational costs and, with higher interest rates, can reduce customer demand and increase order cancellations.

Relevance 80·Dependency 55·Confidence 90
Source evidence
“reducing demand for our products and services, limiting the financing available to our customers and suppliers, increasing order cancellations and resulting in longer sales cycles”
Globally sourced parts and materials
Cost Driver

Danaher sources parts and materials globally; tariffs increase costs of these inputs and of finished goods shipped to customers.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“These incremental costs reflect increased costs of parts and materials used by the Company to produce products, as well as increased costs the Company incurred on finished goods shipped to customers.”
PPACA / healthcare reform
Demand Driver

Healthcare reform, price ceilings and reimbursement changes can reduce usage and patient demand for medical products.

Relevance 65·Dependency 45·Confidence 85
Source evidence
“Price ceilings, decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product may reduce usage and patient demand for the product.”
Key distributors and channel partners
Supplier Dependency

Financial results exposed to adverse changes at key distributors/channel partners, and to cost/availability of supplies and labor.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“Our financial results are subject to fluctuations in the cost and availability of the supplies we use in, and the labor we need for, our operations, as well as adverse changes with respect to key distributors and channel partners.”
GDPR
Regulatory Exposure

GDPR imposes significant restrictions on personal data handling with significant fines for non-compliance.

Relevance 60·Dependency 45·Confidence 85
Source evidence
“the European Union's General Data Protection Regulation ("GDPR") imposes significant restrictions on how we collect, transmit, process and retain personal data”
U.S. Federal Anti-Kickback Statute
Legal Exposure

Anti-kickback, False Claims Act and related laws create litigation/enforcement exposure for healthcare product sales.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government”
Artificial intelligence
Competitive Exposure

Increasing incorporation of AI in Danaher's business exacerbates IT system maintenance and data security risks.

Relevance 60·Dependency 40·Confidence 80
Source evidence
“These risks are exacerbated by the increasing importance of AI and the increasing incorporation of AI in our business.”
Climate policy
Regulatory Exposure

Climate disclosure and greenwashing regulations may increase costs or disrupt sourcing, manufacturing and distribution.

Relevance 60·Dependency 35·Confidence 85
Source evidence
“Any such new or additional requirements relating to climate change or other sustainability topics may increase the costs associated with, or disrupt, sourcing, manufacturing and distribution of our products”
Full company information
Latest profile, trading, valuation, and identifier data stored for DHR.
Share price
$230.40
Market cap
$161.96B
Exchange
NYSE
Currency
USD
CEO
Julie Sawyer Montgomery
Employees
59,000
IPO date
29/12/1978
Beta
0.797
Last dividend
$0.00
Day range
$227.20 – $233.25
52-week range
$160.93 – $242.80
1-day performance
1.06%
1-year performance
43.16%
Current drawdown (1Y)
-5.11%
CIK
0000313616
CUSIP
235851102
ISIN
US2358511028
Created
07/12/2025, 03:35:55
Last update
03/11/2026, 21:03:20

Track Danaher Corporation with an AI analyst

See which prediction-market events move DHR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to DHR from your Railway `news_articles` table.